40+ Candidates Give US FDA Plenty Of Latitude While Growing 2023 Novel Approval Count From 2022

 
• By Bridget Silverman

User fee goal dates in the second half of 2023 suggest cancer and breakthrough therapy approvals should recover from first-half dips and a resumption of inspections in China could revive COVID-delayed products.

growing business
August could be busy for the FDA with action expected on multiple novel product applications. • Source: Shutterstock

More from Approvals

More from Product Reviews